Initiative launched by BIO and Parent Project Muscular Dystrophy (PPMD) will share best practices for development of disease-specific patient preference studies. Via “BRAVE-rare diseases” (Benefit Risk Assessment, Valuation and Epidemiology for rare diseases), BIO and PPMD will produce one document outlining key considerations to guide stakeholders on development of patient preference studies. This can be used for multiple purposes, including informing drug development and regulatory processes.